Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 5/20 | 0.78 |
| ▸ | ALK | Q9UM73 | 13/20 | 0.72 |
| ▸ | EGFR | P00533 | 1/20 | 0.72 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.67 |
| ▸ | IGF1R | P08069 | 4/20 | 0.61 |
| ▸ | INSR | P06213 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11919325 | 0.93 | PTK2 (0.84) | PTK2ALKEGFRMAP4K1IGF1R | |
| SCHEMBL16998990 | 0.91 | PTK2 (0.80) | PTK2ALKEGFRMAP4K1IGF1R | |
| SCHEMBL11919345 | 0.89 | PTK2 (0.77) | PTK2ALKEGFRMAP4K1IGF1R | |
| SCHEMBL11919218 | 0.89 | PTK2 (0.81) | PTK2ALKEGFRMAP4K1IGF1R | |
| SCHEMBL11919322 | 0.88 | PTK2 (0.83) | PTK2ALKEGFRMAP4K1IGF1R | |
| SCHEMBL11918997 | 0.86 | IGF1R (0.82) | PTK2ALKIGF1RINSR | |
| SCHEMBL15222130 | 0.86 | PTK2 (0.79) | PTK2ALKEGFRMAP4K1IGF1R | |
| SCHEMBL11919333 | 0.86 | PTK2 (0.79) | PTK2ALKEGFRMAP4K1IGF1R | |
| SCHEMBL11916525 | 0.85 | PTK2 (0.72) | PTK2ALKEGFRMAP4K1IGF1R | |
| SCHEMBL18831893 | 0.85 | IGF1R (0.61) | PTK2ALKEGFRMAP4K1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170129909-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | QUILU PHARMACEUTICAL CO., LTD. (CN) | 2017-05-11 | — | — | US | disclosed |
| US-20170129909-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | QUILU PHARMACEUTICAL CO., LTD. (CN) | 2017-05-11 | — | — | US | disclosed |
| EP-3165530-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | Qilu Pharmaceutical Co., Ltd (CN) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016000581-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | 南京明德新药研发股份有限公司 | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129909-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | ALK, ROS1, ARSA | PTK2 452/4885ALK 1/4885EGFR 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.